When was Zyl Therapeutics founded?

Zyl Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Zyl Therapeutics located?

Zyl Therapeutics is headquartered in Greenville, United States.

Who is the current CEO of Zyl Therapeutics?

Scott Pancoast of Zyl Therapeutics. They have also founded 1 company.

How many employees does Zyl Therapeutics have?

As of Jan 31, 2026, the latest employee count at Zyl Therapeutics is 3.

Is Zyl Therapeutics a funded company?

Zyl Therapeutics is a funded company, having raised a total of $9.42M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2018.

When was the latest funding round of Zyl Therapeutics?

Zyl Therapeutics' latest funding was a $***** Grant (prize money) round on Jan 27, 2025, with participation from 1 investor.

Where does Zyl Therapeutics rank among its competitors?

Zyl Therapeutics ranks 20th amongst 199 active competitors, of which 57 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was NanoViricides, which secured $6M in Nov, 2025.

Who are the top competitors of Zyl Therapeutics?

Zyl Therapeutics' top competitors include PanTher Therapeutics, Sirnaomics and PolyPid. Among them, NanoViricides secured the most recent funding round in November, 2025.

Zyl Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of hydrogel-derived nanoparticle system for topical applications. The company has developed a patented drug delivery system Nanopods, a hydrogel-derived nanoparticle system. The system can be used to deliver payloads such as nitric oxide, curcumin, cannabis, siRNA, iron, and melanin topically.

Website: www.zylotherapeutics.com/
Social
Email ID: *****@zylotherapeutics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

Greenville, United States

Stage

Series B

Total Funding

$9.42M in 7 rounds

Latest Funding Round

Grant (prize money), Jan 27, 2025, $*****

Investors

VentureSouth & 14 more

Ranked

20^th among 199 active competitors

Employee Count

3 as on Jan 31, 2026

Similar Companies

PanTher Therapeutics & 243 more

View Zyl Therapeutics' full profile

Zyl Therapeutics has raised a total funding of $9.42M over 7 rounds. Its first funding round was on 2018. Its latest funding round was a Grant (prize money) round on Jan 27, 2025 for $*****. 1 investor participated in its latest round. Zyl Therapeutics has 15 institutional investors.

Here is the list of recent funding rounds of Zyl Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 27, 2025	5724444	Grant (prize money)	1322881	5927782	1957081	7672523
May 31, 2023	6105625	Grant (prize money)	1566554	7355330	4667100	NIH
Sep 16, 2022	2541538	Grant (prize money)	7089249	9542827	9378033	NIH SBIR/STTR

Access funding benchmarks and valuations. Sign up today!

View details of Zyl Therapeutics's funding rounds and investors

The founders of Zyl Therapeutics is Scott Pancoast. Scott Pancoast is the CEO of Zyl Therapeutics.

Here are the details of Zyl Therapeutics' key team members:

Scott Pancoast: CEO and Founder (and Board Member) of Zyl Therapeutics.

View details of Zyl Therapeutics's Founder profiles and Board Members

Zyl Therapeutics' employee count trend

Zyl Therapeutics has 3 employees as of Jan 26. Here is Zyl Therapeutics's employee count trend over the years:

Employee count trend for Zyl Therapeutics

Uncover Zyl Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zyl Therapeutics include PanTher Therapeutics, Sirnaomics and PolyPid. Here is the list of Top 10 competitors of Zyl Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PanTher Therapeutics 2014, Cambridge (United States), Series B	Provider of drug delivery system for cancer treatment	$15.4M	CHV, Mission BioCapital & 9 others	69/100
2nd	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	67/100
3rd	PolyPid 2008, Petah Tikva (Israel), Public	Technology platform enabling controlled and prolonged release of any Active Pharmaceutical Ingredient (API)	$96.7M	Shavit Capital, Aurum Ventures & 6 others	66/100
4th	BioSapien 2018, New York City (United States), Seed	Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents	$10.6M	JPIN, Global Ventures & 13 others	58/100
5th	Splice Bio 2020, Barcelona (Spain), Series B	Provider of a proprietary platform for gene therapy	$192M	Ysios Capital, Sanofi Ventures & 9 others	58/100
6th	Arcturus Therapeutics 2013, San Diego (United States), Public	Developer of RNAi technologies for the treatment of rare orphan diseases	$1.3M	Cystic Fibrosis Foundation, JLABS & 1 others	57/100
7th	Topas Therapeutics 2016, Hamburg (Germany), Series B	Developer of nanoparticle-based therapeutics for immunology disorders	$68.5M	Boehringer Ingelheim Venture Fund, Epidarex Capital ... & 7 others	57/100
8th	Avadel Pharmaceuticals 1990, Dublin (Ireland), Acquired	Pharma company with proprietary drug delivery tools and drug for narcolepsy	-	Venrock, RTW Investments & 4 others	53/100
9th	NanoViricides 2005, West Haven (United States), Public	Targeted antiviral therapeutics	-	-	53/100
10th	Santen Pharmaceuticals 1890, Osaka (Japan), Funding Raised	Manufacturer of pharmaceutical products for ophthalmology and rheumatology diseases	-	-	53/100
20th	Zyl Therapeutics 2017, Greenville (United States), Series B	Developer of hydrogel-derived nanoparticle system for topical applications	$9.42M	VentureSouth, KTECH Capital & 13 others	44/100